{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-279788","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-06-23T21:19:36+00:00","discovered_at":"2026-06-23T21:20:00.263897+00:00","generated_at":"2026-06-23T21:20:18.301114+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97","bullets":["Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.","Azelby is independent; will serve on Compensation and Nominating/Corporate Governance committees.","Receives equity: option to purchase 35,910 shares at $27.97, plus RSU for 5,740 shares, vesting over 3 years.","Annual retainer of $45,000 for board service plus committee retainers of $7,500 and $5,000.","Azelby brings 30+ years biopharma experience including Juno and Amgen; company advancing vopimetostat for pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-279788","json":"https://secwatch.observer/filing/0001193125-26-279788.json","markdown":"https://secwatch.observer/filing/0001193125-26-279788.md","text":"https://secwatch.observer/filing/0001193125-26-279788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/0001193125-26-279788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/d79260d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:20:18.301114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4ff756c95","claim":"Robert Azelby was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/0001193125-26-279788-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}